The Rx Recap: May 4-10

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

INF108 to prevent necrotizing enterocolitis receives FDA designations

As reported by Contemporary Pediatrics, Infinant Health’s investigational drug INF108 has received both orphan drug and rare pediatric disease designations from the FDA for the prevention of necrotizing enterocolitis (NEC), a life-threatening condition affecting thousands of preterm infants annually. NEC, which causes intestinal tissue death, remains a leading cause of mortality in neonatal intensive care units, with an estimated incidence of 7% among very low birth weight infants. These FDA designations may expedite INF108’s development and approval process, with the company planning to launch human clinical trials soon.

6 signs your practice needs to hire more staff

As covered by Physicians Practice, running a medical practice while understaffed can quietly erode performance and revenue, with hidden costs that often exceed those of hiring. A data-driven approach helps administrators recognize red flags early—such as rising patient wait times, chronic overtime, and escalating labor costs per visit—before operational strain leads to burnout or lost income. Other key warning signs include reduced office hours, stagnant KPIs despite workflow improvements, and growth plans unsupported by staffing expansion. Acting quickly—by recruiting, outsourcing, or redeploying roles—can stabilize care delivery and protect long-term sustainability.

FDA Grants Accelerated Approval to Avutometinib/Defactinib in KRAS+ LGSOC

Research reported in Cancer Network highlights the FDA approval of avutometinib combined with defactinib for recurrent, KRAS-mutated low-grade serous ovarian cancer. Based on data from the phase 2 RAMP 201 trial, the regimen achieved a 44% response rate and a median progression-free survival of 22 months in KRAS-mutant patients, offering a promising new treatment pathway.

Demystifying PBMs, Their Role in the Drug Supply Chain

Research reported in Drug Topics explores the growing scrutiny of pharmacy benefit managers (PBMs), once seen as cost-saving intermediaries but now under fire for practices that many pharmacists view as exploitative. In a recent Over the Counter podcast episode, health policy expert Antonio Ciaccia sheds light on the fraught dynamics between PBMs and pharmacies, calling their relationship “frictious” and rooted in systemic imbalance.

New analysis of MenaQ7 K2 supplementation study results finds effect on blood pressure in menopausal women

Research reported in Nutritional Outlook highlights new post-hoc findings from a previously published clinical trial showing that MenaQ7 Vitamin K2 as MK-7 significantly improved vascular health in post-menopausal women with high arterial stiffness. The analysis found enhanced blood pressure and vascular flexibility outcomes in this subgroup, reinforcing the potential of targeted vitamin K2 supplementation to support cardiovascular health in aging women.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.